Korea South
WELLS BIO, founded in 2013, emerges as a prominent player in the Biotechnology and Health Care sectors, with its base of operations in Korea South. The company focuses on developing and manufacturing in vitro diagnostic tests leveraging cutting-edge immunochemical, biochemical, and molecular diagnostic technologies to facilitate early disease diagnosis.
In response to the increasing demand for early diagnosis driven by an aging population and global disease proliferation, WELLS BIO positions itself as "The world's best life-caring companion," underscoring its commitment to global health. Despite no recent investments, their strategic industry focus and technological proficiency make them a potential candidate for future funding rounds.
For investors, WELLS BIO presents an opportunity to support innovative healthcare solutions that address contemporary health challenges, thereby contributing to improved global health outcomes.
Zilico Limited
